Not getting enough sleep does more than make you tired. Here’s how short nights can quietly raise your blood pressure, and ...

Finerenone shows significant benefits in patients with kidney disease and type 1 diabetes, which could lead to the first ...

AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...

In A Nutshell • A pig kidney with just one genetic modification functioned in a human for 61 days before being removed as ...

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.

Rising chronic kidney disease prevalence and morbidity rates in 2023 make CKD the ninth leading cause of death globally, ...

A real-world analysis published in JACC Advances concludes that heart failure patients prescribed ivabradine face a significantly higher risk of developing atrial fibrillation (AF) within 180 ...

CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...

A polypill containing three recommended heart failure therapies improved heart function, reduced hospitalizations and was ...

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 inhibitor had a lower risk for CKD progression -- defined as kidney ...